

## Supplementary Materials

# Mannosylated systems for targeted delivery of antibacterial drugs to activated macrophages

Igor D. Zlotnikov <sup>1,\*</sup>, Maksim A. Vigovskiy <sup>2,3</sup>, Maria P. Davydova <sup>3</sup>, Milan R. Danilov <sup>1</sup>, Ulyana D. Dyachkova <sup>2,3</sup>, Olga A. Grigorieva <sup>2,3</sup> and Elena V. Kudryashova <sup>1,\*</sup>

<sup>1</sup> Faculty of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1/3,  
119991 Moscow, Russia

<sup>2</sup> Institute for Regenerative Medicine, Medical Research and Education Center, Lomonosov Moscow State University, 27/10,  
Lomonosovsky Ave., 119192 Moscow, Russia

<sup>3</sup> Faculty of Medicine, Lomonosov Moscow State University, 27/1, Lomonosovsky Ave., 119192 Moscow, Russia

\* Correspondence: zlotnikovid@my.msu.ru (I.D.Z.); helenakoudriachova@yandex.ru (E.V.K.)

## Content

**Figure S1.** Fourier transform infrared spectra and scheme of synthesis of mannan and periodate-oxidized mannan (mannan-oxi). Aqueous solutions. T = 22 °C.

**Figure S2.** Fourier transform infrared spectra of HPCD-PEI1.8-FITC with grafted Man or Gal or triMan. T = 22 °C.

**Figure S3.** Particle size distribution by NTA method: (a) HPCD-PEI1.8-triMan, (b) Mannan-spermine-HPCD, (c) HPCD-spermine-triMan. PBS (pH = 7.4). T = 25 °C.

**Figure S4.** Particle zeta-potential distribution by DLS method: (a) Mannan-spermine-HPCD, (b) HPCD- spermine-triMan, (c) HPCD- spermine-Man, (d) HPCD-spermine-Gal. PBS (pH = 7.4). T = 25 °C.

**Figure S5.** High performance liquid chromatogram of mannosylated drug delivery systems. Knauer chromatography system (Knauer, Berlin, Germany) on Diasfer-110-C18 column (BioChemMack, Moscow, Russia): grains – 6  $\mu$ m, size 4 $\times$ 150 mm. The eluent was CH<sub>3</sub>CN-H<sub>2</sub>O (90:10, v:v); the elution rate was 0.8 mL/min, 25 °C.

**Figure S6.** Dependence of the change in the intensity of the absorption band of Amide II in the FTIR spectra of ConA when binding to ligands. T = 22 °C.

**Figure S7.** Amide I peak deconvolution of (a) ConA and (b) ConA complex with mannan-amCD FTIR spectra. (c) Dependences of the proportions of components in the secondary structure of ConA during ligand (mannan-amCD) binding. (d) Changes in the aggregation of ConA when binding to a ligand (mannan-amCD) relative to the native form. C<sub>0</sub>(ConA subunit) = 0.1 mM. T = 22 °C.

**Figure S8.** Fourier transform infrared spectra of **(a)** EG (eugenol) alone and its complexes with PEI1.8-triMan; **(b)** Safrole alone and its complexes with PEI1.8-triMan; **(c)** FTIR spectra – loading of four components into a molecular container at once: moxifloxacin 0.9 mM, eugenol 17 mM, safrole 12 mM, menthol 12 mM. T = 22 °C.


**Figure S9.** <sup>1</sup>H NMR spectra of **(a)** MF, **(b)** MF complexed with mannan-spermine-HPCD (w:w = 1:1). Proton assignment is given. D<sub>2</sub>O, 400 MHz.

**Figure S10.** Immunocytochemical evaluation of CD206 in THP-1 derived macrophage-like cells (red channel). Phagocytosis assay with polymers (according to table S1) at concentration №2 conjugated with a FITC fluorescent label after incubation for 40 min (green channel). Phase contrast microscopy, fluorescent microscopy, blue channel —nuclei stained with DAPI. Scale bar, 100 µm.


**Figure S11.** Flow cytometry of macrophage, gating strategy. (A) – exclusion of cellular debris based on forward and side light scattering, (B) – selection of single cells by forward scatter signal area and height, (C) – selection of single cells by side scatter signal width and height. (D,E) – overlay of a control sample (blue) and a sample after incubation with one of the polymers (red) represented by a dot plot (D) and a histogram (E). The percentage of cells in the gate is indicated under the name of the gate.


**Table S1.** Characteristics of polymer conjugates used for experiments with macrophages: capture efficiency, specificity – depending on the molecular architecture, ligand components and carbohydrate label.

**Figure S1.** Fourier transform infrared spectra and scheme of synthesis of mannan and periodate-oxidized mannan (mannan-oxi). Aqueous solutions. T = 22°C.




**Figure S2.** Fourier transform infrared spectra of HPCD-PEI1.8-FITC with grafted Man or Gal or triMan. T = 22 °C.






(b)


**Figure S3.** Particle size distribution by NTA method: (a) HPCD-PEI1.8-triMan, (b) Mannan-spermine-HPCD, (c) HPCD-spermine-triMan. PBS (pH = 7.4). T = 25 °C.








(b)






**Figure S4.** Particle zeta-potential distribution by DLS method: (a) Mannan-spermine-HPCD, (b) HPCD- spermine-triMan, (c) HPCD- spermine-Man, (d) HPCD-spermine-Gal. PBS (pH = 7.4). T = 25 °C.






(c)




(d)


**Figure S5.** High performance liquid chromatogram of mannosylated drug delivery systems. Knauer chromatography system (Knauer, Berlin, Germany) on Diasfer-110-C18 column (BioChemMack, Moscow, Russia): grains – 6  $\mu\text{m}$ , size 4 $\times$ 150 mm. The eluent was  $\text{CH}_3\text{CN-H}_2\text{O}$  (90:10, v:v); the elution rate was 0.8 mL/min, 25  $^\circ\text{C}$ .





**Figure S6.** Dependence of the change in the intensity of the absorption band of Amide II in the FTIR spectra of ConA when binding to ligands. T = 22 °C.




**Figure S7.** Amide I peak deconvolution of (a) ConA and (b) ConA complex with mannan-amCD FTIR spectra. (c) Dependences of the proportions of components in the secondary structure of ConA during ligand (mannan-amCD) binding. (d) Changes in the aggregation of ConA when binding to a ligand (mannan-amCD) relative to the native form.  $C_0(\text{ConA subunit}) = 0.1 \text{ mM}$ .  $T = 22 \text{ }^\circ\text{C}$ .








(c)




(d)




**Figure S8.** Fourier transform infrared spectra of **(a)** EG (eugenol) alone and its complexes with PEI1.8-triMan; **(b)** Safrole alone and its complexes with PEI1.8-triMan; **(c)** FTIR spectra – loading of four components into a molecular container at once: moxifloxacin 0.9 mM, eugenol 17 mM, safrole 12 mM, menthol 12 mM. T = 22 °C.






(b)

(c)











**Figure S10.** Immunocytochemical evaluation of CD206 in THP-1 derived macrophage-like cells (red channel). Phagocytosis assay with polymers (according to table S1) at concentration №2 conjugated with a FITC fluorescent label after incubation for 40 min (green channel). Phase contrast microscopy, fluorescent microscopy, blue channel —nuclei stained with DAPI. Scale bar, 100  $\mu$ m.



**Figure S11.** Flow cytometry of macrophage, gating strategy. (A) – exclusion of cellular debris based on forward and side light scattering, (B) – selection of single cells by forward scatter signal area and height, (C) – selection of single cells by side scatter signal width and height. (D,E) – overlay of a control sample (blue) and a sample after incubation with one of the polymers (red) represented by a dot plot (D) and a histogram (E). The percentage of cells in the gate is indicated under the name of the gate.



**Table S1.** Characteristics of polymer conjugates used for experiments with macrophages: capture efficiency, specificity – depending on the molecular architecture, ligand components and carbohydrate label.

Ligand designation	Carrier*	Label (n)**	$\omega(\text{FITC})$ , %	Final concentration for macrophages №1	Final concentration for macrophages №2
<b>1b</b>	Mannan-spermine-HPCD-FITC (1 : 15 : 10 : 2)	Mannan itself	5	0.1	0.05
<b>2a</b>	HPCD-PEI1.8-FITC* (3 : 1 : 0.5 : n)**	Man (12)	2.2	0.23	0.115
<b>2b</b>		triMan (3)			
<b>2c</b>		Gal (12)			
<b>3a</b>	HPCD-spermine-FITC (1 : 4 : 0.5 : n)**	Man (3)	8	0.065	0.0325
<b>3b</b>		triMan (1-2)			
<b>3c</b>		Gal (3)			